surpass cvot tirzepatide In patients with type 2 diabetes and atherosclerotic cardiovascular disease, was noninferior to dulaglutide with respect to major cardiovascular events. ⁣, ⁣, Read the full SURPASS-CVOT SURPASS-CVOT trial: For patients with

These effects may contribute to metabolic improvements beyond what can be explained by weight loss alone

L., Baskin, D

In the lipid profile, the proportion achieving triglyceride levels below 1.7 mmol/l was higher in the tirzepatide-treated groups

Some physicians specialize in weight management and are familiar with these medications

The slowed gastric motility that reduces appetite also slows transit time through the entire digestive tract, leading to harder stools and less frequent bowel movements

Additionally, the gut microbiota plays an important role in bone metabolism regulation, and supplementing with certain probiotics may have a preventive effect on bone mass reduction associated with TZP treatment